Ras oncogenes are frequently mutated in thyroid carcinomas. To verify the role played by N-ras in thyroid carcinogenesis, we generated transgenic mice in which a human N-ras(Gln61Lys) oncogene (Tg-N-ras) was expressed in the thyroid follicular cells. Tg-N-ras mice developed thyroid follicular neoplasms; 11% developed follicular adenomas and B40% developed invasive follicular carcinomas, in some cases with a mixed papillary/ follicular morphology. About 25% of the Tg-N-ras carcinomas displayed large, poorly differentiated areas, featuring vascular invasion and forming lung, bone or liver distant metastases. N-ras(Gln61Lys) expression in cultured PC Cl 3 thyrocytes induced thyroid-stimulating hormone-independent proliferation and genomic instability with micronuclei formation and centrosome amplification. These findings support the notion that mutated ras oncogenes could be able to drive the formation of thyroid tumors that can progress to poorly differentiated, metastatic carcinomas.
Ras oncogenes are frequently mutated in thyroid carcinomas. To verify the role played by N-ras in thyroid carcinogenesis, we generated transgenic mice in which a human N-ras(Gln61Lys) oncogene (Tg-N-ras) was expressed in the thyroid follicular cells. Tg-N-ras mice developed thyroid follicular neoplasms; 11% developed follicular adenomas and B40% developed invasive follicular carcinomas, in some cases with a mixed papillary/ follicular morphology. About 25% of the Tg-N-ras carcinomas displayed large, poorly differentiated areas, featuring vascular invasion and forming lung, bone or liver distant metastases. N-ras(Gln61Lys) expression in cultured PC Cl 3 thyrocytes induced thyroid-stimulating hormone-independent proliferation and genomic instability with micronuclei formation and centrosome amplification. These findings support the notion that mutated ras oncogenes could be able to drive the formation of thyroid tumors that can progress to poorly differentiated, metastatic carcinomas. Oncogene (2006 Oncogene ( ) 25, 5467-5474. doi:10.1038 published online 19 June 2006 Keywords: kinase; carcinoma; thyroid; ras; progression; differentiation Thyroid tumors are the most common malignancies of the endocrine system (DeLellis and Williams, 2004) . Well-differentiated thyroid carcinomas (WDC) account for >90% of all thyroid cancers and include papillary (PTC) and follicular (FTC) carcinomas; FTC may arise from pre-existing follicular adenomas (Sherman, 2003) . Anaplastic thyroid carcinomas (ATC) account for o2-5% of all thyroid cancers. Despite its rarity, more than half of deaths attributed to thyroid cancer result from ATC (DeLellis and Williams, 2004) . Follicular cell neoplasms, which, in terms of differentiation, morphology and growth, are intermediate between WDC and ATC are called 'poorly differentiated carcinomas' (PDC) (Carcangiu et al., 1984) . Histological examination of PDC and ATC may also reveal WDC, which suggests that, at least in some cases, they may derive from a pre-existing WDC.
Structural rearrangements of the RET (RET/PTC) and NTRK1 (TRK-T) receptors and point mutations in the BRAF serine/threonine kinase (BRAF-V600E) are common in PTC (Fagin, 2004; Xing, 2005) . BRAF point mutations have also been detected in PDC and ATC (Nikiforova et al., 2003a) . Thyroid carcinomas may express mutated forms of all three ras (H-ras, K-ras and N-ras) genes (Nikiforova et al., 2003b) . Ras mutations are infrequent in PTC, where they are restricted to aggressive PTC subtypes (Garcia-Rostan et al., 2003) , and to the follicular PTC variant (Zhu et al., 2003) . Between 20 and 50% of FTC are positive for ras mutations (Tallini, 2002) . The N-ras mutation in codon 61 is the most frequent ras mutation in FTC and it is more frequent in malignant than in benign thyroid tumors (Motoi et al., 2000; Garcia-Rostan et al., 2003; Nikiforova et al., 2003b; Vasko et al., 2003; Zhu et al., 2003) .
Transgenic mice featuring the thyroid-specific expression of various oncogenes under the transcriptional control of the bovine thyroglobulin (Tg) promoter recapitulate the thyroid disease spectrum associated with alterations of specific oncogenes in human patients (Ledent et al., 1991 (Ledent et al., , 1992 . Thyroid targeting of the SV40 LT oncogene, which blocks p53 function, causes very aggressive ATC (Ledent et al., 1991) . Targeted expression of BRAF(V600E) results in PTC that undergo dedifferentiation . Thyroid transgenics expressing K-ras (Santelli et al., 1993) or H-ras (Rochefort et al., 1996) under the control of the Tg promoter develop adenomas or differentiated carcinomas, respectively. Here, we have studied the consequences of the expression of the N-ras(Gln61Lys) oncogene in the thyroid gland of transgenic mice.
We generated transgenic mice harboring the human N-ras cDNA carrying the activating Gln-Lys mutation at codon 61, under the control of the bovine Tg promoter (À2036 to þ 9, relative to the transcription start site) (Figure 1a) . The transgene was transmitted in a Mendelian manner and its integration was confirmed by Southern blot (Figure 1b) . Three transgenic mice and one non-transgenic littermate were killed at 6 months of age and transgene expression was analysed by reverse transcriptase-polymerase chain reaction (RT-PCR) with human N-ras amplimers spanning codon 61. As shown in Figure 1c , thyroids from transgenic, but not from control mice, expressed the transgene. Sequencing of the RT-PCR products confirmed the presence of the Figure 1 (a) Schematic representation of the pTg-N-ras construct. Restriction sites are E: EcoRI; B: BamHI; X: XbaI; S: SalI. The human N-ras cDNA carrying the Gln61->Lys mutation was obtained from the HT1080 cell line by reverse transcriptase-polymerase chain reaction (RT-PCR) amplification, sequenced and inserted in the PSG5 plasmid (Stratagene, La Jolla, CA, USA) containing the b-globin intron and the SV40 polyadenylation signal sequence. A 2.7-kb StuI/SalI fragment was, then, cloned in the EcoRV/SalI sites of the pBluescript II-SK þ vector containing the bovine thyroglobulin (Tg) promoter (À2036 to þ 9), kindly provided by JE Dumont (Ledent et al., 1991) , to generate pTg-N-ras. Transgenic animals were obtained by standard procedures in the Animal Facility of Consorzio Mario Negri Sud (Santa Maria Imbaro, Chieti, Italy). The pTg-N-ras DNA was purified (Qiagen, Crawley, West Sussex, UK) and 2 mg of purified construct was microinjected into zygotes as described elsewhere (Russell et al., 2000) . The microinjected embryos were implanted in BDF1 pseudo-pregnant females. Founder animals were mated with wild-type C57BL/6J mice and the progeny was screened by Southern blotting. (b) Southern blot analysis of genomic DNA extracted from tail biopsies hybridized with a 2-kb bovine Tg DNA fragment. Two transgenic mice (nos. 15 and 45) and one non-transgenic littermate (no. 65) are shown. A Tg-TRK ( þ ) (Russell et al., 2000) served as positive control and wild-type C57BL/6J (À) mouse DNAs were used as negative control. (c) Reverse transcriptase-polymerase chain reaction detection of Tg-N-ras expression: thyroid tissue from three transgenic animals (nos. 15, 45 and 46) and one non-transgenic littermate (À) are shown. Levels of mouse b-actin transcripts were used to confirm equal loading. RNA was extracted by the RNeasy Mini Kit (Qiagen, Crawley, West Sussex, UK). Polymerase chain reaction amplification was performed using the GeneAmp RNA PCR Core Kit system (Applied Biosystems, Warrington, UK). To exclude DNA contamination, each PCR reaction was also performed on untranscribed RNA (not shown). The amplimers for human N-ras were as follows: N-ras in mouse thyroid carcinomas D Vitagliano et al codon 61 mutation (not shown). No ectopic transgene expression was detected in non-thyroid tissues (liver, lung, kidney, brain, testis and spleen) (not shown), which confirms the thyroid-specific activity of the Tg promoter fragment (Ledent et al., 1991) . Transgenic mice (n ¼ 88) were killed at 6, 12 and 18 months of age and thyroid histology was compared to that of wildtype littermate controls (Figures 1d and 2 ). Neoplasms were classified according to the WHO criteria for the evaluation of mouse thyroid tumors (Jokinen and Botts, 1994) . Control thyroids showed normal features, with variable-sized follicles covered by flattened epithelial cells ( Figure 2a ). There was a range of proliferative lesions in the transgenic thyroids, going from follicular cell hyperplasia to adenoma and carcinoma (Figures 1d and 2b-f). Follicular cell hyperplasia was characterized by large, indistinct areas of small follicles with scant colloid and tall epithelial cells (Figure 2b ). Ten/88 (11%) of the animals developed well-demarcated follicular adenomas with a mixed papillary and follicular architecture ( Figure 2c ). Twenty-six/88 (B30%) of the mice developed follicular cell carcinomas. These cases showed the presence of a well-differentiated follicular or mixed papillary-follicular malignant component invading the stroma, with low-grade cytology, low-mitotic count and no necrosis (Figure 2d ). Importantly, 9/88 Tg-N-ras mice (roughly 25% of the carcinoma-bearing animals) had invasive carcinomas, featuring large, poorly differentiated areas (trabecular, insular, solid and necrotic), high-grade histology and high-mitotic activity (Figure 2f ). Occasionally, neoplastic emboli were seen in blood vessels (Figure 2e ). Such more severe lesions were more commonly observed in old animals ( Figure 1d ). These features closely resembled those of PDC in humans (Carcangiu et al., 1984) . However, squamoid, spindle and giant cell patterns of growth, typical of human anaplastic (undifferentiated) carcinomas, were not observed in Tg-N-ras mice. Metastases were searched for by examining systematically cervical, axillary and tracheobronchial lymph nodes, as well as lungs, major bones, brain and liver. Metastases appeared as round white nodules within the parenchyma of the liver (two mice) ( Figure 2g ) and/or of lung (three mice) (Figure 2h ) or in the right femur (one mouse, not shown) in a subset of PDC-bearing transgenic mice. Histologically, neoplastic cells within the metastatic nodules were arranged in densely packed clusters of atypical cells. The thyroid origin of the metastatic cells was suggested by the morphological resemblance with the primary thyroid lesion and by heterogeneous staining for TTF-1 (not shown).
Immunohistochemical stain for thyroid differentiation markers was performed (Figure 3) . Poorly differentiated Tg-N-ras carcinomas (PDC) were strongly positive for Ki67/MIB-1, which is consistent with a high-mitotic index (Figure 3b ), whereas normal thyroid tissue (Figure 3a ) as well as benign or well-differentiated Tg-N-ras neoplasms (not shown) was negative or weakly positive for Ki67/MIB-1. Normal thyroid tissue, benign and well-differentiated thyroid lesions from Tg-N-ras mice maintained certain levels of expression of Tg, sodium/iodide symporter (NIS) and thyroid-specific transcription factors (PAX-8 and TTF-1) (Figure 3c , e, g and i). In contrast, high-grade Tg-N-ras PDCs were weakly positive or almost negative for Tg and NIS (Figure 3d and f) and showed only scattered cells positive for PAX-8 (Figure 3h) . Most of them, however, kept TTF-1 staining (Figure 3j) . Likely, the expression of the thyroid transcription factors (TTF-1 and, partially, PAX-8) might be required to maintain the expression of the Tg-driven transgene in the tumor lesion. Low expression levels of the oncogene or an equilibrium that is reached between oncogene activity and oncogene expression (that depends on the Tg promoter, a differentiation-dependent promoter) could explain while thyroid differentiation is at least partially maintained in this model. This is an intrinsic weakness of the model that does not allow one to fully appreciate the effects of the oncogene on thyroid differentiation. In other Tg transgenic models, like Tg-BRAF, high compensatory thyroid-stimulating hormone (TSH) levels were reported secondary to thyroid dysfunction . Likely, in those mice, increased TSH levels contributed to the disease phenotype in conjunction with the transgene activity . Thus, we measured serum TSH levels (RIA kit, Amersham Biosciences Europe, Freiburg, Germany) from tail vein blood samples of Tg-N-ras mice at 4 (two mice), 8 (13 mice), 10 (12 mice) and 16 (10 mice) months of age. At 4-8 months, 60% of the Tg-N-ras mice showed TSH levels between 6.5 and 13.0 ng/ml, thus, on average, 2.5-fold higher with respect to those of age-matched control mice (Student's t-test: Po0.01). The other 40% of 4-8 months old showed TSH levels (2.8-4.8 ng/ml) very close to the normal range (3.3-5.5 ng/ml). At 10-16 months, 40% of the Tg-N-ras mice showed TSH levels between 6.3 and 9.6 ng/ml, thus, on average, 1.5-fold higher with respect to those of agematched control mice (3.0-5.7 ng/ml) (Student's t-test: Po0.01). T4 levels (Diagnostics Products Corp., Los Angeles, CA, USA) of Tg-N-ras animals were not significantly different from wild-type littermates (not shown). It is possible that such an increase in TSH levels, although rather modest, may contribute, at least in some of the Tg-N-ras mice, to the disease phenotype.
We used PC Cl 3 cells as an in vitro model system whereby to study N-ras(Gln61Lys) effects in follicular thyroid cells. PC Cl 3 is a continuous line of thyroid cells, derived from Fischer rats. Normally, PC Cl 3 cells require a mixture of six hormones (6H), including TSH, for proliferation. The expression of different oncogenes renders PC Cl 3 TSH-independent for growth (Melillo et al., 2005; Mitsutake et al., 2005) . Stable transfectants of PC Cl 3 cells expressing N-ras(Gln61Lys) were generated. For comparison, we also transfected RET/ PTC3 (RFG-RET) (Powell et al., 1998) or -TRK-T1 (TPR-TRK) (Greco et al., 1992) , two oncogenes that, both in transgenic animals and in human patients, correlate with well-differentiated and non-progressive tumors (Fagin, 2004) . Marker-selected mass populations of several ten cell clones as well as isolated cell clones were obtained; results with two representative cell clones for each plasmid are shown. Oncogene expression was verified by immunoblot (Figure 4a ). The oncogenetransfected cell populations showed a morphologically transformed phenotype (not shown). Moreover, expression of each one of the three oncogenes abolished the dependency of PC Cl 3 cell proliferation on the 6H. Of note, N-ras(Gln61Lys) conferred PC Cl 3 cells with a stronger mitogenic drive with respect to the other two oncogenes (Figure 4b ). It has been reported that, in PC Cl 3 cells, the acute expression of H-ras(V12) (Saavedra et al., 2000) or BRAF(V600E) (Knauf et al., , 2006 Mitsutake et al., 2005) oncogenes increases the Figure 3 Immunohistochemical analysis ( Â 250) of Tg-N-ras thyroids. Ki67/MIB-1 is not expressed in normal thyroid tissue from a wild-type littermate (a), but it is expressed by the majority of the poorly differentiated Tg-N-ras malignant cells (b). Thyroglobulin (Tg) is expressed in well-differentiated benign neoplastic cells (c); its expression is lost in poorly differentiated Tg-N-ras neoplastic cells (d). A clear membrane sodium/iodide symporter (NIS) staining pattern is shown in areas composed by well-differentiated Tg-N-ras neoplastic cells (e); NIS expression is lost in poorly differentiated neoplastic cells (f). Tg-N-ras hyperplastic follicular cells are positive for PAX-8 (g), whereas only scattered poorly differentiated malignant cells are positive for PAX-8 (h). TTF-1 is expressed by the Tg-N-ras hyperplastic follicular thyroid cells (i) as well as by follicular carcinoma cells (j). Briefly, 5 mm tissue sections were deparaffinized, alcohol-rehydrated, subjected to heat-induced antigen retrieval and incubated overnight with anti-Ki67/MIB-1 (1:50) (diaminobenzidine (DAB); Dako, Carpinteria, CA, USA), TTF-1 (Dako Corporation), Tg (Dako Corporation), PAX-8 or NIS antibodies (Postiglione et al., 2002) . Then, the slides were incubated with biotinylated anti-immunoglobulin (Ig)G and with pre-mixed avidinbiotin complex (Vectostain ABC kits, Vector Laboratories, Burlingame, CA, USA). The immune reaction was revealed with 0.06 mmol/ l DAB (Dako, Carpinteria, CA, USA) and 2 mmol/l hydrogen peroxide. As a negative control, tissue slides were incubated with preimmune serum.
N-ras in mouse thyroid carcinomas D Vitagliano et al frequency of micronuclei, an accepted indicator of chromosomal instability. Micronuclei are small nuclearlike structures containing chromosome fragments that form during mitosis as a result of chromosome missegregation. Moreover, doxycycline-inducible Hras(V12) PC Cl 3 cells had supernumerary centrosomes (Saavedra et al., 2000) . Centrosomes, by contributing to the organization of the microtubule spindles in mitosis, N-ras in mouse thyroid carcinomas D Vitagliano et al play critical roles in chromosome segregation. Supernumerary and abnormally shaped centrosomes have been involved in genetic instability and tumor progression (Doxsey et al., 2005) . We hypothesized that reduction of genomic stability, with a progressive accumulation of genetic alterations, could contribute (6H): thyrotropin (thyroid-stimulating hormone (TSH), 10 mU/ml), hydrocortisone (10 nM), insulin (10 mg/ml), apo-transferrin (5 mg/ml), somatostatin (10 ng/ml) and glycyl-histidyl-lysine (10 ng/ml) (Sigma Chemical Co., St Louis, MO, USA). All the molecular constructs were cloned in pCDNA3(Myc-His) (Invitrogen, Groningen, The Netherlands). Stable transfections were performed by the calcium phosphate co-precipitation technique as described previously (Melillo et al., 2005) . Mass populations of several ten cell clones as well as two single-cell clones (Cl1 and 2) were isolated for each transfection by G418 selection. Proteins were extracted and immunoblotting experiments were performed according to standard procedures. Anti-RET is an affinitypurified polyclonal antibody raised against the tyrosine kinase protein fragment of human RET; monoclonal antibodies (mAbs) AG-1 (Calbiochem, San Diego, CA, USA) and B-3 (Santa Cruz Biothecnology Inc., Santa Cruz, CA, USA) were used to detect N-ras and TRK-T1, respectively. (b) S-phase entry was evaluated by the 5-bromo-3-deoxyuridine Labeling and Detection kit from Boehringer Mannheim, Germany. Cells were grown on coverslips, and 6H-deprived for 72 h. 5-Bromodeoxyuridine (BrdU) was added at a concentration of 10 mM for 1 h. Cells were fixed in 3% paraformaldehyde and permeabilized with 0.2% Triton X-100. 5-Bromodeoxyuridine-positive cells were revealed with anti-BrdU mouse monoclonal antibody and with Texas-Red-conjugated secondary antibodies (Jackson Immuno Research Laboratories Inc., Philadelphia, PA, USA). The average results7s.d. of three independent experiments in which at least 500 cells were counted are shown. (c) Micronuclei were counted by 4 0 -6-diamidino-2-phenylindole stain; they were defined as rounded chromatin fragments located adjacent to a nucleus, with a diameter not exceeding one-third of the nuclear diameter (Gisselsson et al., 2001) . Micronuclei were distinguished from apoptotic bodies, as the former are seen within cells that have an intact nucleus, whereas the latter are associated with fragmented nuclei. The average number7s.d. of micronuclei per 100 cells (at least 500 cells were scored) calculated by pooling results with both clones for each transfection is reported. One representative picture is shown in the inset. (d) Centrosomes were counted by staining with mouse monoclonal anti-g-tubulin (Sigma Chemical Co.) or rabbit anti-pericentrin (Babco, UK) antibodies; the two stains gave identical results. The percentage7s.d. of cells with more than two centrosomes (at least 500 cells were scored) calculated by pooling results with both clones for each transfection is reported. One representative picture is shown in the inset. N-ras in mouse thyroid carcinomas D Vitagliano et al to the oncogenic activity of N-ras(Gln61Lys) for thyrocytes. Thus, the percentage of oncogene-transfected PC Cl 3 with micronuclei or with more than two centrosomes was calculated as an indicator of genomic instability. Less than 3% of parental PC Cl 3 cells showed any of these alterations (Figure 4c and d) . N-ras(Gln61Lys) expression induced micronuclei formation (Figure 4c ) and the presence of many cells with supernumerary centrosomes (Figure 4d ). Moreover, as many as 28% of the N-ras cells showed abnormally shaped nuclei with blebs and variability in nuclear size (not shown). In contrast, o14% of RET/PTC or TRK-T1 cells showed either micronuclei (Figure 4c ) or increased centrosome numbers (Figure 4d ). Thus, these observations suggest that the N-ras(Gln61Lys) oncogene has in vitro stronger mitogenic activity than RET/ PTC or TRK-T1 and has the ability of promoting, differently from the other oncogenes, genomic instability. The latter property may, in turn, facilitate neoplastic progression towards a more aggressive phenotype. Neither the prevalence of FTC nor that of PDC was 100% in Tg-N-ras animals, suggesting that secondary genetic changes, which might be favored by genomic instability, are needed to drive full malignant transformation. This is also suggested by the late time at which aggressive thyroid tumors arise in N-ras animals.
It is interesting to note that BRAF(V600E) was recently reported to induce the formation of PTC which transitions to PDC and undifferentiated carcinomas . Interestingly, BRAF(V600E) can be found in human patients affected by PDC and ATC (Xing, 2005) . Thus, the two models suggest that both BRAF and N-ras oncogenes are able to initiate the formation of thyroid carcinomas able to progress to an aggressive phenotype. This is not a general feature of thyroid transgenic models (Jhiang et al., 1996; Santoro et al., 1996; Powell et al., 1998; Russell et al., 2000) . Discrepancies between the various models could be caused, at least in part, by different expression levels, genetic background, subtle differences in the construct or to undefined environmental factors. However, it is interesting to speculate that differences may also be owing to the different functions exerted by the individual oncoproteins. Accordingly, we could demonstrate that N-ras(Gln61Lys), similarly to BRAF(V600E) and to H-ras(V12) (Saavedra et al., 2000) , but differently from RET/PTC3 and TRK-T1, induced signs of genomic instability, including micronuclei and supernumerary centrosomes. Thus, ras family members and BRAF, but not rearranged tyrosine kinases, are associated to genomic instability and tumor progression. Knauf et al. (2006) recently demonstrated that activation of mitogen-activated protein kinase (MAPK) is necessary but not sufficient to bypass G2/M and mitotic spindle checkpoints, and that both MAPK-dependent and -independent pathways explain the genomic instability of HRAS(V12)-expressing cells. The various oncoproteins that we have tested are all capable of inducing MAPK activation. It is feasible that either quantitative differences in signaling to MAPK or additional pathways can explain the different oncogenic activity of the different oncoproteins (Ellis and Clark, 2000; Downward, 2003; Malumbres and Barbacid, 2003) . Fagin (2002) suggested that distinct oncogenicinitiating events may determine the final fate of thyroid tumors. The Tg-N-ras model suggests that ras oncogenes can drive the formation of tumors that undergo de-differentiation and neoplastic progression. Tg-N-ras animals could be used to study ras-driven genomic instability and be exploited to investigate the influence of environment and concomitant genetic alterations (other than the transgene) in follicular thyroid carcinogenesis and progression. These mice may be also used to improve the early diagnosis of aggressive thyroid cancer and to test new molecular therapies that target ras oncogenes.
